BioRestorative Therapies Inc (BRTX)

BioRestorative Therapies Inc. is a biotechnology company focused on developing cell- and tissue-based therapeutic products and medical therapies, with an emphasis on adult stem cell protocols. Its pipeline includes BRTX-100, a lead cell therapy candidate made from autologous cultured mesenchymal stem cells collected from a patient’s bone marrow and being evaluated for painful lumbosacral disc disorders, including potential use as a non-surgical treatment or as a complement to surgery. The company is also developing ThermoStem, a cell-based candidate intended to address obesity and metabolic disorders through brown adipose derived stem cells. In addition, BioRestorative Therapies operates a commercial biocosmeceutical platform and provides an investigational curved needle device for delivering cells and other therapeutic materials to the spine, discs, and other parts of the body. The company has research and collaboration arrangements with Rohto Pharmaceutical, Pfizer, and the University of Pennsylvania and is headquartered in Melville, New York.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.